Which has higher earnings and valuation, EVO or ALMR?

Alamar Biosciences has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.69 -$117.12M N/A N/A Alamar Biosciences $74.21M 26.08 -$29.82M -$1.96 N/A

Does the media prefer EVO or ALMR?

In the previous week, Evotec had 10 more articles in the media than Alamar Biosciences. MarketBeat recorded 12 mentions for Evotec and 2 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.84 beat Evotec's score of -0.01 indicating that Alamar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, MRVI or EVO?

Evotec has higher revenue and earnings than Maravai LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maravai LifeSciences $185.74M 9.13 -$130.77M -$0.52 N/A Evotec $891.97M 0.69 -$117.12M N/A N/A

Does the media favor MRVI or EVO?

In the previous week, Evotec had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Evotec and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.42 beat Evotec's score of -0.01 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, PSNL or EVO?

Personalis has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.65M 24.37 -$81.27M -$1.09 N/A Evotec $891.97M 0.69 -$117.12M N/A N/A

Is PSNL or EVO more profitable?

Evotec has a net margin of -26.20% compared to Personalis' net margin of -153.84%. Evotec's return on equity of -24.93% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% Evotec -26.20% -24.93% -11.35%

Does the media prefer PSNL or EVO?

In the previous week, Evotec had 6 more articles in the media than Personalis. MarketBeat recorded 12 mentions for Evotec and 6 mentions for Personalis. Personalis' average media sentiment score of 1.33 beat Evotec's score of -0.01 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, BLFS or EVO?

BioLife Solutions has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioLife Solutions $106.69M 16.03 -$4.59M $1.16 30.13 Evotec $891.97M 0.69 -$117.12M N/A N/A

Is BLFS or EVO more profitable?

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets BioLife Solutions 53.29% 2.70% 2.49% Evotec -26.20% -24.93% -11.35%

Does the media prefer BLFS or EVO?

In the previous week, Evotec had 8 more articles in the media than BioLife Solutions. MarketBeat recorded 12 mentions for Evotec and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.10 beat Evotec's score of -0.01 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, FTRE or EVO?

Evotec has lower revenue, but higher earnings than Fortrea. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.72B 0.60 -$986.20M -$0.91 N/A Evotec $891.97M 0.69 -$117.12M N/A N/A

Is FTRE or EVO more profitable?

Fortrea has a net margin of -3.18% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 10.72% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Evotec -26.20% -24.93% -11.35%

Does the media prefer FTRE or EVO?

In the previous week, Evotec had 4 more articles in the media than Fortrea. MarketBeat recorded 12 mentions for Evotec and 8 mentions for Fortrea. Fortrea's average media sentiment score of 0.42 beat Evotec's score of -0.01 indicating that Fortrea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Evotec (EVO) Competitors

$1.73 -0.04 (-2.26%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 09/11/2026 07:30 PM Eastern

Compare

EVO vs. ALMR, MRVI, PSNL, BLFS, and FTRE

Should you buy Evotec stock or one of its competitors? Evotec's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), Personalis (PSNL), BioLife Solutions (BLFS), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Evotec compare to Alamar Biosciences?

Evotec (NASDAQ:EVO) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Alamar Biosciences has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.69	-$117.12M	N/A	N/A
Alamar Biosciences	$74.21M	26.08	-$29.82M	-$1.96	N/A

5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alamar Biosciences has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Alamar Biosciences' return on equity of 0.00% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, Evotec had 10 more articles in the media than Alamar Biosciences. MarketBeat recorded 12 mentions for Evotec and 2 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.84 beat Evotec's score of -0.01 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Evotec currently has a consensus price target of $3.00, indicating a potential upside of 73.41%. Alamar Biosciences has a consensus price target of $31.80, indicating a potential upside of 14.02%. Given Evotec's higher possible upside, research analysts plainly believe Evotec is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Alamar Biosciences beats Evotec on 8 of the 13 factors compared between the two stocks.

How does Evotec compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Evotec has higher revenue and earnings than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.13	-$130.77M	-$0.52	N/A
Evotec	$891.97M	0.69	-$117.12M	N/A	N/A

Maravai LifeSciences presently has a consensus target price of $6.83, indicating a potential upside of 4.65%. Evotec has a consensus target price of $3.00, indicating a potential upside of 73.41%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evotec has a net margin of -26.20% compared to Maravai LifeSciences' net margin of -37.07%. Maravai LifeSciences' return on equity of -15.70% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Evotec	-26.20%	-24.93%	-11.35%

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Evotec had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Evotec and 4 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.42 beat Evotec's score of -0.01 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Maravai LifeSciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Evotec has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Summary

Maravai LifeSciences beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Evotec compare to Personalis?

Personalis (NASDAQ:PSNL) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

61.9% of Personalis shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evotec has a net margin of -26.20% compared to Personalis' net margin of -153.84%. Evotec's return on equity of -24.93% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Evotec	-26.20%	-24.93%	-11.35%

Personalis has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Evotec has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

In the previous week, Evotec had 6 more articles in the media than Personalis. MarketBeat recorded 12 mentions for Evotec and 6 mentions for Personalis. Personalis' average media sentiment score of 1.33 beat Evotec's score of -0.01 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Personalis currently has a consensus price target of $14.54, suggesting a potential downside of 10.33%. Evotec has a consensus price target of $3.00, suggesting a potential upside of 73.41%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Personalis has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	24.37	-$81.27M	-$1.09	N/A
Evotec	$891.97M	0.69	-$117.12M	N/A	N/A

Summary

Personalis beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Evotec compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioLife Solutions has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Evotec has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

BioLife Solutions presently has a consensus price target of $31.38, suggesting a potential downside of 10.23%. Evotec has a consensus price target of $3.00, suggesting a potential upside of 73.41%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioLife Solutions has a net margin of 53.29% compared to Evotec's net margin of -26.20%. BioLife Solutions' return on equity of 2.70% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Evotec had 8 more articles in the media than BioLife Solutions. MarketBeat recorded 12 mentions for Evotec and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.10 beat Evotec's score of -0.01 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

BioLife Solutions has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$106.69M	16.03	-$4.59M	$1.16	30.13
Evotec	$891.97M	0.69	-$117.12M	N/A	N/A

Summary

BioLife Solutions beats Evotec on 10 of the 14 factors compared between the two stocks.

How does Evotec compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Evotec had 4 more articles in the media than Fortrea. MarketBeat recorded 12 mentions for Evotec and 8 mentions for Fortrea. Fortrea's average media sentiment score of 0.42 beat Evotec's score of -0.01 indicating that Fortrea is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Fortrea has a net margin of -3.18% compared to Evotec's net margin of -26.20%. Fortrea's return on equity of 10.72% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Evotec	-26.20%	-24.93%	-11.35%

Fortrea has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Evotec has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Evotec has lower revenue, but higher earnings than Fortrea.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.60	-$986.20M	-$0.91	N/A
Evotec	$891.97M	0.69	-$117.12M	N/A	N/A

5.8% of Evotec shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fortrea currently has a consensus price target of $22.00, suggesting a potential upside of 27.91%. Evotec has a consensus price target of $3.00, suggesting a potential upside of 73.41%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Fortrea beats Evotec on 8 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$615.57M	$9.74B	$7.16B	$12.85B
Dividend Yield	N/A	1.48%	2.57%	11.17%
P/E Ratio	N/A	66.42	274.94	25.36
Price / Sales	0.69	108.85	685.45	116.82
Price / Cash	N/A	26.35	76.65	51.52
Price / Book	0.67	5.28	10.33	6.20
Net Income	-$117.12M	$56.67B	$3.50B	$358.50M
7 Day Performance	-6.99%	-2.15%	-3.32%	-2.35%
1 Month Performance	-14.36%	-1.93%	-0.53%	-3.23%
1 Year Performance	-50.14%	25.04%	23.51%	8.79%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	2.5769 of 5 stars	$1.73 -2.3%	$3.00 +73.4%	-50.1%	$615.57M	$891.97M	N/A	4,553	Short Interest Increase Gap Down
ALMR Alamar Biosciences	2.5466 of 5 stars	$30.47 -0.2%	$31.80 +4.4%	N/A	$2.11B	$74.21M	N/A	222
MRVI Maravai LifeSciences	1.9172 of 5 stars	$7.49 -2.0%	$6.25 -16.5%	+144.6%	$1.94B	$185.74M	N/A	610	Analyst Upgrade
PSNL Personalis	2.0182 of 5 stars	$17.02 +1.4%	$14.54 -14.6%	+177.1%	$1.78B	$69.65M	N/A	400
BLFS BioLife Solutions	2.4898 of 5 stars	$36.25 -2.2%	$31.38 -13.4%	+37.0%	$1.77B	$96.21M	31.25	440	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. ALMR, MRVI, PSNL, BLFS, and FTRE

How does Evotec compare to Alamar Biosciences?

Summary

How does Evotec compare to Maravai LifeSciences?

Summary

How does Evotec compare to Personalis?

Summary

How does Evotec compare to BioLife Solutions?

Summary

How does Evotec compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. ALMR, MRVI, PSNL, BLFS, and FTRE

How does Evotec compare to Alamar Biosciences?

Which has higher earnings and valuation, EVO or ALMR?

Do institutionals & insiders believe in EVO or ALMR?

Is EVO or ALMR more profitable?

Does the media prefer EVO or ALMR?

Do analysts recommend EVO or ALMR?

Summary

How does Evotec compare to Maravai LifeSciences?

Which has better earnings & valuation, MRVI or EVO?

Do analysts rate MRVI or EVO?

Is MRVI or EVO more profitable?

Do institutionals and insiders hold more shares of MRVI or EVO?

Does the media favor MRVI or EVO?

Which has more risk and volatility, MRVI or EVO?

Summary

How does Evotec compare to Personalis?

Do institutionals & insiders hold more shares of PSNL or EVO?

Is PSNL or EVO more profitable?

Which has more risk and volatility, PSNL or EVO?

Does the media prefer PSNL or EVO?

Do analysts prefer PSNL or EVO?

Which has better valuation and earnings, PSNL or EVO?

Summary

How does Evotec compare to BioLife Solutions?

Do insiders and institutionals hold more shares of BLFS or EVO?

Which has more volatility and risk, BLFS or EVO?

Do analysts recommend BLFS or EVO?

Is BLFS or EVO more profitable?

Does the media prefer BLFS or EVO?

Which has higher valuation and earnings, BLFS or EVO?

Summary

How does Evotec compare to Fortrea?

Does the media prefer FTRE or EVO?

Is FTRE or EVO more profitable?

Which has more risk & volatility, FTRE or EVO?

Which has preferable valuation and earnings, FTRE or EVO?

Do insiders and institutionals hold more shares of FTRE or EVO?

Do analysts rate FTRE or EVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools